Janssen #AdVac technology is a technology based on the #adenovirus vector that can be used together with PER.C6 technology to develop recombinant #vaccines against life-threatening infectious diseases.
#Ad5_nCoV is a genetically engineered #vaccine candidate with the replication-defective #adenovirus type 5 as a vector to express the spike protein of the novel #coronavirus (SARS-CoV-2).
